Work

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Year: 2009

Type: article

Source: Anti-Cancer Drugs

DOI: 10.1097/cad.0b013e32833123ed

Authors: Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer, Volker Heinemann

Institutions: American Society of Clinical Oncology, Ludwig-Maximilians-Universität München, University of Cologne, Klinikum Magdeburg, University Hospital Magdeburg, Heidelberg University, Bayreuth Medical Center, Klinikum Esslingen, Medizinische Hochschule Hannover, LMU Klinikum

Language: German

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2072299610

FWCI: 1.942

Cites: 24

Cited by: 34

Related to: 10